



AXIM BIOTECH

Company Overview

AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew Plus™, a CBD-based controlled release chewing gum containing 10mg of hemp-derived CBD, CanChew+ 50™, containing 50 mg of CBD undergoing clinical trials in patients with IBS, and MedChew Rx™, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy.

AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco

May 15 2018, 9:00 AM EDT

AXIM Biotech Secures Additional Funding to Advance Cannabinoid-Based Clinical Development Program for Multiple Indications

Apr 23 2018, 9:00 AM EDT

AXIM Biotech Files Patent Application on Product Formulation Comprised of Cannabinoids With Anti-Bacterial and Anti-Fungal Activities

Apr 18 2018, 9:00 AM EDT

Stock Overview

Symbol	AXIM
Exchange	OTCQB
Market Cap	203.12m
Last Price	\$3.58
52-Week	\$3.24 - \$13.455

05/18/2018 03:57 PM EDT

Management Team

Dr. George E. Anastassov

Chief Executive Officer, President & Chairman of the Board

Dr. Philip A. Van Damme, DMD MD PhD

Chief Scientific Officer

Lekhram Changoer

Chief Technology Officer

AXIM Biotechnologies, Inc.

45 Rockefeller Plaza
20th Floor, Suite 83
New York, NY 10111

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.